173 related articles for article (PubMed ID: 37446260)
1. Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers.
Sulaiman R; De P; Aske JC; Lin X; Dale A; Koirala N; Gaster K; Espaillat LR; Starks D; Dey N
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446260
[TBL] [Abstract][Full Text] [Related]
2. A landscape of patient-derived cancer-associated fibroblast signals in endometrial cancers.
Sulaiman R; Koirala N; Aske JC; Lin X; Rojas-Espaillat L; Starks D; Dale A; Gaster K; De P; Dey N
Am J Cancer Res; 2024; 14(2):467-489. PubMed ID: 38455423
[TBL] [Abstract][Full Text] [Related]
3. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.
Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
Arch Gynecol Obstet; 2019 Aug; 300(2):377-382. PubMed ID: 31076855
[TBL] [Abstract][Full Text] [Related]
5. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
[TBL] [Abstract][Full Text] [Related]
6. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
[TBL] [Abstract][Full Text] [Related]
7. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.
Hoskins EL; Samorodnitsky E; Wing MR; Reeser JW; Hopkins JF; Murugesan K; Kuang Z; Vella R; Stein L; Risch Z; Yu L; Adebola S; Paruchuri A; Carpten J; Chahoud J; Edge S; Kolesar J; McCarter M; Nepple KG; Reilley M; Scaife C; Tripathi A; Single N; Huang RSP; Albacker LA; Roychowdhury S
JCO Precis Oncol; 2023 Jan; 7():e2200300. PubMed ID: 36623238
[TBL] [Abstract][Full Text] [Related]
9. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,
Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC
Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465
[TBL] [Abstract][Full Text] [Related]
11. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
12. An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response.
Dioken DN; Ozgul I; Yilmazbilek I; Yakicier MC; Karaca E; Erson-Bensan AE
Cancer Immunol Immunother; 2023 Dec; 72(12):4065-4075. PubMed ID: 37768345
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
14. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Zhang S; Minaguchi T; Xu C; Qi N; Itagaki H; Shikama A; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
BMC Cancer; 2020 Feb; 20(1):127. PubMed ID: 32066405
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
20. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
